Physician-reviewed · Licensed pharmacy · Ships to your door
A physician-reviewed educational overview. Not promotional. Not a treatment recommendation. Individual outcomes may differ.
BPC-157 — Body Protection Compound-157 — is a pentadecapeptide consisting of 15 amino acids. It was originally derived from a protein found in human gastric juice. Unlike many naturally occurring peptides that are produced systemically, BPC-157 in its studied form is synthetic — meaning it is manufactured rather than extracted from human tissue.
It has been studied in clinical and preclinical settings for several decades, with the majority of foundational research conducted in Croatia by Predrag Sikirić and colleagues. The research body is substantial in animal models; human clinical trial data remains more limited, which is important context for understanding any clinical claims.
BPC-157 appears to interact with several physiological systems. Based on available clinical literature, the primary mechanisms studied include:
BPC-157 has been studied for its interaction with the nitric oxide (NO) signaling pathway. Nitric oxide plays a central role in vascular regulation, inflammation, and tissue repair. In animal models, BPC-157 has been associated with upregulation of nitric oxide synthase (NOS) activity, which may support angiogenesis — the formation of new blood vessels — a critical component of tissue repair. Individual outcomes may differ.
Studies have suggested BPC-157 may interact with growth hormone receptors in a way that supports tissue repair signaling without directly elevating systemic growth hormone levels. This is a clinically meaningful distinction, as direct GH elevation carries its own risk profile. In clinical settings, this interaction has been associated with tendon and ligament healing support.
Given its origin in gastric juice, BPC-157's studied effects on GI mucosal integrity are among the most well-documented. In clinical settings, it has been associated with protection of the gastric mucosa against NSAID-induced damage, and with support for GI healing in models of inflammatory bowel conditions. Results vary by individual.
The following represents areas where BPC-157 has been studied. This is not a list of approved indications, and it is not a treatment recommendation. All outcomes noted use FTC-compliant language because the evidence base, while substantial in animal models, is not yet equivalent to what would support direct human outcome claims.
Animal model studies have associated BPC-157 with accelerated healing timelines for tendon, ligament, and muscle injuries. In these models, BPC-157 has been associated with increased fibroblast proliferation, collagen synthesis, and tendon-to-bone junction remodeling. Whether these findings translate directly to human clinical outcomes at equivalent dosing is an open question that ongoing research is beginning to address. Results vary.
Oral BPC-157 has been studied for its potential to support GI mucosal integrity. In clinical settings, it has been associated with protective effects in ulcer models, intestinal anastomosis healing support, and inflammatory bowel disease models. This is one of the application areas with the strongest preclinical evidence base.
BPC-157 has been studied for its anti-inflammatory properties across multiple tissue types. In clinical settings, it has been associated with modulation of inflammatory cytokines and support for recovery from inflammatory insult. Individual outcomes may differ significantly based on underlying pathology and individual physiology.
BPC-157 may be administered subcutaneously or orally. The preferred route varies by clinical application: oral administration is more commonly studied in GI applications; subcutaneous administration is more common in musculoskeletal and systemic applications.
Typical dosing ranges discussed in clinical literature span 250–500 mcg per day, though specific dosing for any individual is determined by a licensed physician based on clinical profile, goals, and contraindications. Do not self-administer or adjust dosing without physician guidance.
BPC-157 is dispensed through Verum Health only with a valid physician prescription. This is not a regulatory formality. It exists because:
These are not theoretical concerns. They are the clinical rationale for the prescription model.
The honest answer to "how well-studied is BPC-157 in humans?" is: well-studied in animal models, less so in controlled human clinical trials. This does not mean the evidence doesn't exist — it means the translation from preclinical findings to human outcomes is an ongoing process, not a settled question.
Verum Health presents BPC-157 in the context of what the clinical literature actually says — not what enthusiast forums claim, and not with artificial certainty in either direction. If you're considering this protocol, your physician will help you evaluate whether the available evidence and your specific clinical profile support candidacy.
Complete your intake. A physician will review your case within 24–48 hours.
Begin Your Protocol View Full ProtocolPrescription required. Results may vary. Individual outcomes may differ.